why choose us

First received: September 07, 2023

Clinical Trial: Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

Study Status: Completed

Recruit Status: RECRUITING

Condition: Chronic Inducible Urticaria

Study Type: INTERVENTIONAL


Official Title: Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria (CALM-CIndU)

Brief Summary: This phase 1b trial will evaluate the effects of EP262 in subjects with Chronic Inducible Urticaria (CIndU), including symptomatic dermographism and cold urticaria.

Read more